Abstract
Background:
Tetralogy of Fallot (TOF) is the most prevalent cyanotic congenital heart defect. Pulmonary regurgitation (PR) is a common sequela following most surgical repairs for TOF. Tadalafil might reduce pulmonary vascular resistance after Tetralogy of Fallot total correction (TOFTC).Objectives:
This study evaluated the efficacy of tadalafil in reducing PR volume and improving heart function among TOFTC children with severe PR, using transthoracic echocardiography, particularly focusing on changes in N-terminal pro-b-type natriuretic peptide (NT-proBNP).Methods:
The present study was conducted on TOFTC patients consecutively between September 2019 and August 2020 at Shiraz University of Medical Sciences, Shiraz, Iran. M-mode and two-dimensional (2D) Doppler echocardiography were performed, and NT-proBNP levels were measured in 20 patients before and one month after tadalafil administration. SPSS version 23.0 was utilized to analyze all results.Results:
The patients' ages ranged from 25 to 128 months. The mean age and weight of the patients were 67.9 ± 34.5 months and 21.1 ± 6.9 kg, respectively. Tadalafil administration did not significantly improve Doppler and tissue Doppler parameters; however, it increased the pulmonary valve pressure gradient and velocity-time integral. Additionally, tadalafil had no significant effect on improving NT-proBNP levels. The Spearman correlation test did not show any significant correlation between the pulmonary valve pressure gradient and velocity-time integral with age, weight, and NT-proBNP.Conclusions:
Tadalafil increased the pulmonary valve pressure gradient and velocity-time integral in TOFTC patients with severe PR; however, it did not affect NT-proBNP levels or tissue Doppler parameters.Keywords
Congenital Heart Disease Tetralogy of Fallot NT-proBNP Transthoracic Echocardiography
1. Background
Tetralogy of Fallot (TOF) is regarded as the most prevalent cyanotic congenital heart defect (1). Since the introduction of TOF repair surgery in 1945 (2), early mortality has improved; however, long-term follow-ups of survivors with Tetralogy of Fallot total correction (TOFTC) have shown late complications such as exercise intolerance, right heart function impairment due to pulmonary valve regurgitation (PR), arrhythmias, and sudden death (3-5). Therefore, it is recommended to continually follow up with patients following TOFTC using electrocardiography and echocardiography (1, 6).
Many long-term complications of TOFTC are correlated with the hemodynamic impacts of PR and are related to chronic right ventricular volume overload (7). These patients may remain asymptomatic for many years, with complications directly related to PR severity (8).
Tadalafil is a selective inhibitor of phosphodiesterase type 5 recognized as a treatment to decrease pulmonary arterial pressure in both children and adults (9, 10). Tadalafil is well tolerated, and the side effects are usually transient and of mild to moderate severity (11). Few recent studies have shown that tadalafil might improve exercise performance, functional class, and pulmonary endothelial function, providing patients with prolonged periods of well-being and postponing the need for pulmonary valve replacement in TOFTC patients (12).
Some studies have shown the beneficial effect of sildenafil administration in improving myocardial activity in heart failure in adults. We hypothesized that tadalafil may reduce pulmonary artery pressure and improve myocardial function.
2. Objectives
The current study aimed to investigate the impact of tadalafil on heart function and the severity of PR in TOFTC children using transthoracic echocardiography, with a particular focus on changes in N-terminal pro-b-type natriuretic peptide (NT-proBNP).
3. Methods
The present study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (code No.: IR.SUMS.MED.REC.1399.062), in accordance with the Helsinki Declaration and its later amendments.
3.1. Study Population
This prospective study was conducted on consecutive patients with TOFTC and severe PR referred to Namazi Hospital, affiliated with Shiraz University of Medical Sciences, Shiraz, Iran, between September 2019 and August 2020.
The reconstructive surgery method for these patients was a transannular patch. Patients with TOFTC and severe PR, not receiving drugs effective in pulmonary endothelial function (e.g., lipid-lowering agents, diuretics, and nitrates) and without systemic diseases met the study inclusion criteria. If the patients had aortopulmonary collateral arteries, they were closed with devices (13). The exclusion criteria included patients undergoing interim interventions or changes in clinical condition between the two echocardiography times and those with more than mild tricuspid regurgitation. Additionally, patients with renal or hepatic impairment, dysrhythmias or a pacemaker, tadalafil administration in the previous 3 months, or further congenital heart lesions were excluded. Considering that tadalafil has no effect on reducing pulmonary artery stenosis and that this stenosis can cause problems in the study results, patients with pulmonary artery stenosis were also excluded.
Following the recording of patients’ files, an echocardiogram was obtained, and all data, including demographic and clinical features such as underlying anatomy and surgical repair details, were collected.
The patients were administered a single dose of tadalafil tablet at 1 mg per kg (maximum 40 mg) daily orally for 4 weeks. The NT-proBNP test and echocardiographic parameters were determined before and 4 weeks after the patients took tadalafil. The findings of echocardiography after 4 weeks were considered the effect of tadalafil.
3.2. Echocardiographic Measurements
All transthoracic echocardiographies were performed using an ultrasound system (Vivid S6, GE Company, USA) by a pediatric cardiologist. Echocardiographic characteristics were acquired based on the American Society of Echocardiography standard levels. Each parameter was measured twice on average for analysis. To reduce the effect of inter-observer variability on the echocardiographic findings, each data point was measured three times, and the average was used in the study.
Fractional shortening, ejection fraction, and tricuspid annular plane systolic excursion were obtained. Doppler indices of peak PR velocity, total diastolic time, and pulmonary velocity-time integral were measured for the evaluation of the pulmonary forward flow and PR flow indices. The PR Index was calculated by dividing the PR duration by the diastolic duration of constant pulse-wave spectral Doppler signals in the primary pulmonary artery. This index demonstrated PR severity; that is, if the velocity profile was higher, regurgitation was less (14). Pulmonary regurgitation time measurement was performed from its onset in early diastole to the end of the regurgitant Doppler signal. Additionally, diastolic duration was calculated from the end of forward pulmonary flow to the initiation of the next forward pulmonary flow wave.
The early diastolic inflow blood velocity (E wave) and late diastolic inflow velocity (A wave) at the tip of mitral and tricuspid valve leaflets in the apical 4-chamber view were measured using pulse wave Doppler. Moreover, tissue Doppler of the mitral and tricuspid valves and the septum was determined (15, 16).
While MRI is the method of choice for evaluating the condition and function of the right ventricle as well as PR severity, echocardiography was used in this study due to the need to anesthetize the patients and economic considerations.
3.3. Electrocardiography
The electrocardiographs of the patients were taken, and the most relevant data, such as QRS duration and R wave amplitude in the V1 lead, were obtained before and after tadalafil administration.
3.4. N-terminal Pro-b-type Natriuretic Peptide Measurement
After blood collection, 5 cc of the samples were centrifuged and kept at -20°C. Sampling was done on two occasions, one month apart, before and after taking tadalafil. A commercially available ELISA Kit E90485Hu (USCN Life Science Inc., China) was used. The normal ranges for NT-proBNP in children aged 1 - 2 years, 2 - 6 years, and 6 - 16 years were 400, 300, and 160 pg/mL, respectively (17).
3.5. Statistical Analysis
SPSS version 23.0 (SPSS, Chicago, IL, USA) was utilized to statistically analyze the data. Mean and standard deviation were employed to express the data. Numbers and percentages were appropriately used to present the continuous and categorical variables. The Mann-Whitney test was utilized to compare continuous characteristics before and after taking tadalafil. The relationship between age, weight, and NT-proBNP with echocardiographic variables was evaluated using the Spearman correlation test. A p-value < 0.05 was considered statistically significant.
4. Results
The study population consisted of 28 patients, with the parents of eight patients refusing to cooperate with the study authors.
Table 1 shows the demographic data of the 20 studied patients. The participants' ages ranged from 25 to 128 months. The mean age was 67.9 ± 34.5 months, with a median of 87 months, and the mean age of TOF surgical correction was 11.2 ± 26.72 months. In this study, 11 (55%) patients were male and 9 (45%) were female.
| Variables | Values |
|---|---|
| Gender | |
| Male | 11 (55) |
| Female | 9 (45) |
| Age (m) | |
| 25% percentile | 35.01 |
| 50% percentile | 65.02 |
| 75% percentile | 102.51 |
| Total age | 67.9 ± 34.5 |
| Weight (kg) | 21.15 ± 6.92 |
The echocardiographic parameters of each case before and 4 weeks after tadalafil administration are shown in Table 2. The pulmonary valve pressure gradient and velocity-time integral were significantly higher after tadalafil administration. However, tadalafil had no significant effect on other parameters such as the PR index, NT-proBNP, tricuspid annular plane systolic excursion, fractional shortening, and ejection fraction.
Echocardiographic Parameters and the N-terminal Pro-b-type Natriuretic Peptide Level Before and 4 Weeks After Tadalafil Administration Using Mann-Whitney Test a
| Characteristics | Before Tadalafil | After Tadalafil | P-Value |
|---|---|---|---|
| TAPSE (mm) | 15.25 ± 3.14 | 15.8 ± 3.3 | 0.28 |
| Peak TR PG (mm Hg) | 28.3 ± 7.0 | 28.0 ± 6.4 | 0.49 |
| TV VTI (cm) | 74.7 ± 10.4 | 76.1 ± 5.7 | 0.51 |
| Peak PV PG (mm Hg) | 23.2 ± 6.7 | 25.5 ± 8.5 | 0.04 |
| PV VTI (cm) | 56.3 ± 12.7 | 61.0 ± 10.2 | 0.00 |
| PR index | 0.7 ± 0.05 | 0.7 ± 0.04 | 0.42 |
| NT-proBNP (pg/mL) | 62.3 | 58.7 | 0.72 |
| EF% | 68.5 ± 4.3 | 66.6 ± 6.8 | 0.22 |
| FS% | 36.9 ± 3.4 | 35.3 ± 4.7 | 0.14 |
Table 3 shows the tissue Doppler parameters of the lateral mitral and tricuspid valves and the septum before and 4 weeks after tadalafil administration, with no significant changes observed after tadalafil administration.
Tissue Doppler Parameters of the Mitral and Tricuspid Valves and the Septum Before and After Tadalafil Administration Using Mann-Whitney Test a
| Characteristics | Before Tadalafil | After Tadalafil | P-Value |
|---|---|---|---|
| MV lat e´ (cm/s) | 8.56 ± 0.06 | 0.81 ± 0.07 | 0.81 |
| MV lat a´ (cm/s) | 7.34 ± 0.06 | 0.72 ± 0.05 | 0.26 |
| MV lat e'/a' ratio | 1.13 ± 0.08 | 1.17 ± 0.15 | 0.58 |
| Sept e' (cm/s) | 10.33 ± 2.34 | 10.93 ± 2.18 | 0.10 |
| Sept a´ (cm/s) | 5.39 ± 1.35 | 5.63 ± 1.26 | 0.09 |
| Sept e'/a' ratio | 1.94 ± 3.12 | 1.95 ± 4.78 | 0.21 |
| TV e´ (cm/s) | 13.31 ± 2.27 | 12.94 ± 2.79 | 0.21 |
| TV a´ (cm/s) | 6.09 ± 1.28 | 5.75 ± 0.81 | 0.23 |
| TV e'/a' ratio | 2.21 ± 3.12 | 2.26 ± 3.45 | 1.02 |
The correlation of age, weight, and NT-proBNP with changes in pulmonary valve pressure gradient, velocity-time integral, and e' and a' of the mitral and tricuspid valves and septum were assessed using the Spearman correlation test (Table 4). Although the pulmonary valve pressure gradient and velocity-time integral significantly changed after tadalafil administration among the echocardiographic factors, none of these changes were correlated with age, weight, or NT-proBNP (P > 0.05).
Correlation of Echocardiographic Parameters with Age, Weight, and N-terminal Pro B-type Natriuretic Peptide
| Echocardiographic Variables | Pearson Correlation | P-Value |
|---|---|---|
| Age (m) | ||
| PV PG (mm Hg) | -0.25 | 0.36 |
| PV VTI (cm) | -0.17 | 0.46 |
| Sept e' (cm/s) | 0.11 | 0.64 |
| Sept a´ (cm/s) | -0.23 | 0.25 |
| MV e´ (cm/s) | 0.21 | 0.47 |
| MV a´ (cm/s) | -0.44 | 0.06 |
| TV e´ (cm/s) | 0.26 | 0.09 |
| TV a´ (cm/s) | -0.46 | 0.12 |
| Weight (kg) | ||
| PV PG (mm Hg) | -0.09 | 0.70 |
| PV VTI (cm) | -0.11 | 0.65 |
| Sept e' (cm/s) | 0.22 | 0.34 |
| Sept a´ (cm/s) | -0.30 | 0.19 |
| MV e´ (cm/s) | 0.32 | 0.08 |
| MV a´ (cm/s) | -0.25 | 0.48 |
| TV e´ (cm/s) | 0.31 | 0.54 |
| TV a´ (cm/s) | -0.38 | 0.07 |
| NT-proBNP (pg/mL) | ||
| PV PG (mm Hg) | -0.51 | 0.17 |
| PV VTI (cm) | -0.03 | 0.93 |
| Sept e' (cm/s) | 0.16 | 0.65 |
| Sept a´ (cm/s) | 0.54 | 0.11 |
| MV e´ (cm/s) | 0.24 | 0.16 |
| MV a´ (cm/s) | 0.46 | 0.87 |
| TV e´ (cm/s) | 0.20 | 0.56 |
| TV a´ (cm/s) | 0.67 | 0.08 |
Additionally, the QRS duration and R wave amplitude of the patients in lead V1 electrogram were obtained before and 4 weeks after tadalafil administration, revealing no significant differences (Table 5).
QRS Duration and R Wave Amplitude in Lead V1 Electrocardiogram Before and 4 Weeks After Tadalafil
| Electrocardiographs Data | Before Tadalafil | After Tadalafil | P-Value |
|---|---|---|---|
| QRS duration (ms) | 118.53 | 116.12 | 0.17 |
| R wave (mv) | 0.45 | 0.43 | 2.68 |
5. Discussion
The objective of this investigation was to assess the effectiveness of tadalafil in reducing PR volume and improving cardiac function in TOFTC children, with a special focus on changes in NT-proBNP. The obtained results showed that tadalafil administration significantly improved some echocardiographic parameters, such as pulmonary valve pressure gradient and velocity-time integral. However, it did not improve tissue Doppler parameters, NT-proBNP, or electrocardiographic data, contrary to our initial hypothesis that tadalafil would have a positive effect on these latter three items.
Phosphodiesterase type 5 is not present in the normal right ventricle; however, it is up-regulated in hypertrophied myocardium. Phosphodiesterase type 5 inhibitors (e.g., sildenafil and tadalafil) can increase contractility in experimental models of right ventricular hypertrophy but not in normal myocardium (18). Compared to sildenafil, tadalafil has a more prolonged half-life (18 hours) and can be taken as a single dose per day. Different studies have shown the effectiveness of tadalafil in improving pulmonary artery hypertension and potentially right ventricular function in these patients (19-21). A previous study (12) demonstrated that tadalafil administration following TOFTC surgery positively affected exercise performance, the New York Heart Association functional class, and endothelial function among patients with more than mild PR.
One study on NT-proBNP levels after surgical correction of TOF reported that its level did not correlate with right ventricular ejection fraction, but it did correlate with right ventricular dilation and PR severity in response to myocardial stretch. Another study reported that medications that reduce the severity of PR in these patients can decrease NT-proBNP.
Our study showed that tadalafil increases pulmonary valve pressure gradient and pulmonary valve velocity-time integral, suggesting that it can reduce pulmonary vascular resistance or improve right ventricular function in these patients. However, there was no significant correlation between NT-proBNP and pulmonary valve pressure gradient or heart function. This may be because our study was conducted among patients with severe PR, and tadalafil administration could not decrease PR volume. The lack of decrease in NT-proBNP may be due to the persistence of severe PR despite a reduction in pulmonary vascular resistance, which prevented a decrease in NT-proBNP levels despite improvement in right ventricular function.
An increase in velocity-time integral was speculated to be due to decreases in pulmonary vascular resistance and right ventricular afterload. This also suggests an increase in right ventricular stroke volume, potentially representing an improvement in cardiac output. Some researchers have reported that the administration of anti-pulmonary hypertension medications can improve exercise capacity in these patients.
The decrease in pulmonary vascular resistance may indicate an improvement in right ventricular function and a reduction in NT-proBNP levels in future follow-ups. According to the findings of the mentioned studies, the outcome of long-term administration of pulmonary antihypertensive medications should be determined in long-term research and may improve the hemodynamics of the right ventricle.
Cardiac arrhythmia is a common finding in a large proportion of patients after TOFTC (22). An increase in pulmonary artery pressure gradient similar to more than moderate PR is predictive of ventricular arrhythmia. Tadalafil was able to increase the pulmonary valve pressure gradient, which could be indirect evidence of a decrease in pulmonary artery pressure as expected. This reduction after tadalafil administration might lead to a reduction in the arrhythmia rate over a long time.
5.1. Conclusions
Tadalafil may increase pulmonary valve pressure gradient and velocity-time integral in patients with TOFTC, which could be indirect evidence of a reduction in pulmonary artery resistance or improved right ventricular function. However, tadalafil did not improve other echocardiographic parameters or decrease NT-proBNP because it could not decrease the severity of PR. These findings might indicate improved right ventricular function, although larger studies are needed to better elucidate its exact role in patients with TOFTC. Additionally, it is necessary to examine the impact of tadalafil in long-term studies with a larger sample size to determine its effect on NT-proBNP levels.
Acknowledgements
References
-
1.
Luijnenburg SE, Helbing WA, Moelker A, Kroft LJ, Groenink M, Roos-Hesselink JW, et al. 5-year serial follow-up of clinical condition and ventricular function in patients after repair of tetralogy of Fallot. Int J Cardiol. 2013;169(6):439-44.
-
2.
Taussig HB, Blalock A. The tetralogy of Fallot; diagnosis and indications for operation; the surgical treatment of the tetralogy of Fallot. Surg. 1947;21(1):145.
-
3.
Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(9234):975-81.
-
4.
Valente AM, Gauvreau K, Assenza GE, Babu-Narayan SV, Schreier J, Gatzoulis MA, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100(3):247-53.
-
5.
Tatewaki H, Shiose A. Pulmonary valve replacement after repaired Tetralogy of Fallot. General Thoracic Cardiovascular Surg. 2018;66:509-15.
-
6.
Allen HD, Driscoll DJ, Shaddy RE, Feltes TF. Moss & Adams' heart disease in infants, children, and adolescents: including the fetus and young adult. Philadelphia, United States: Lippincott Williams & Wilkins; 2013.
-
7.
Frigiola A, Redington AN, Cullen S, Vogel M. Pulmonary regurgitation is an important determinant of right ventricular contractile dysfunction in patients with surgically repaired tetralogy of Fallot. Circul. 2004;110(11_suppl_1):II-153-II-157.
-
8.
Babu-Narayan SV, Diller G, Gheta RR, Bastin AJ, Karonis T, Li W, et al. Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential prognostic value of preoperative cardiopulmonary exercise testing. Circul. 2014;129(1):18-27.
-
9.
Sabri MR, Beheshtian E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol. 2014;35:699-704.
-
10.
Yamazaki H, Kobayashi N, Taketsuna M, Tajima K, Murakami M. Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. Curre Med Res Opinion. 2017;33(5):963-71.
-
11.
Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evidence. 2015:99-109.
-
12.
Sabri MR, Shoja M, Shoja M, Hosseinzadeh M. The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot. ARYA Atheroscler. 2018;14(4):177-82. [PubMed ID: 30627194]. [PubMed Central ID: PMC6312565]. https://doi.org/10.22122/arya.v14i4.1561.
-
13.
Amoozgar H, Edraki MR, Naghshzan A, Mehdizadegan N, Mohammadi H, Ajami G, et al. Midterm follow up of transcatheter closure of coronary artery fistula with Nit-Occlud® patent ductus arteriosus coil. BMC Cardiovasc Disord. 2021;21(1). [PubMed ID: 33879042]. [PubMed Central ID: PMC8056487]. https://doi.org/10.1186/s12872-021-01999-3.
-
14.
Amoozgar H, Salehi M, Borzoee M, Ajami G, Edraki MR, Mehdizadegan N, et al. Balloon valvuloplasty for pulmonary stenosis in children: immediate outcome and cardiac remodeling during midterm follow-up. Iran J Pediatr. 2017;27(6).
-
15.
Amoogzar H, Shakiba AM, Derakhshan D, Ajami G, Cheriki S, Borzouee M, et al. Evaluation of left ventricular function by tissue Doppler and speckle-derived strain rate echocardiography after percutaneous ductus closure. Pediatr Cardiol. 2015;36:219-25.
-
16.
Geva T. Indications for pulmonary valve replacement in repaired tetralogy of fallot: the quest continues. Am Heart Assoc. 2013;128(17):1855-7.
-
17.
Lenz AM. Natriuretic peptides in children: physiology and clinical utility. Curr Opinion Pediatr. 2011;23(4):452-9.
-
18.
Nagendran J, Archer SL, Gurtu V, Webster L, Ross DB, Rebeyka IM, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle: direct implications for patients with pulmonary hypertension. Am Heart Assoc. 2006;116(3). [PubMed ID: 17606845]. https://doi.org/10.1161/CIRCULATIONAHA.106.655266.
-
19.
Kim H, Park J, Park SJ, Park JK, Lee H. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Int Med. 2007;22(1):37.
-
20.
Jalalian R, Moghadamnia AA, Tamaddoni A, Khafri S, Iranian M. Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta-thalassaemia intermedia. Heart, Lung Circul. 2017;26(7):677-83.
-
21.
Tobler D, Bouchardy J, Reto E, Heg D, Müller C, Frenk A, et al. Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and design. Int J Cardiol. 2017;243:354-9. [PubMed ID: 28566262]. https://doi.org/10.1016/j.ijcard.2017.05.079.
-
22.
Pfeiffer ME, Andrea EM, Serra SM, Assumpcao CR, Herdy GV. Late clinical and functional assessment of arrhythmias in children after repair of Tetralogy of Fallot. Arq Bras Cardiol. 2010;95(3):295-302. [PubMed ID: 20640382]. https://doi.org/10.1590/s0066-782x2010005000092.